key: cord-0845426-sxvu7lci
authors: ESKENAZI, Brenda; RAUCH, Stephen; IURLARO, Enrico; GUNIER, Robert B.; REGO, Albertina; GRAVETT, Michael G.; CAVORETTO, Paolo Ivo; DERUELLE, Philippe; GARCÍA-MAY, Perla K.; MHATRE, Mohak; USMAN, Mustapha Ado; ELBAHNASAWY, Mohamed; ETUK FWACS, Saturday; NAPOLITANO, Raffaele; DEANTONI, Sonia; LIU, Becky; PREFUMO, Federico; SAVASI, Valeria; MARQUES, Patrícia F.; BAAFI, Eric; ZAINAB, Ghulam; NIETO, Ricardo; SERRANO, Berta; AMINU, Muhammad Baffah; CARDONA-PEREZ, Jorge Arturo; CRAIK, Rachel; WINSEY, Adele; TAVCHIOSKA, Gabriela; BAKO, Babagana; OROS, Daniel; BENSKI, Caroline; GALADANCI, Hadiza; SAVORANI, Mónica; OBERTO, Manuela; SENTILHES, Loïc; RISSO, Milagros; TAKAHASHI, Ken; VECCIARELLI, Carmen; IKENOUE, Satoru; PANDEY, Anil K.; SOTO CONTI, Constanza P.; CETIN, Irene; NACHINAB, Vincent Bizor; ERNAWATI, Ernawati; DURO, Eduardo A.; KHOLIN, Alexey; FIRLIT, Michelle L.; EASTER, Sarah Rae; SICHITIU, Joanna; JOHN-AKINOLA, Yetunde; CASALE, Roberto; CENA, Hellas; AGYEMAN-DUAH, Josephine; ROGGERO, Paola; LANGER, Ana; BHUTTA, Zulfiqar A.; KENNEDY, Stephen H.; VILLAR, Jose; PAPAGEORGHIOU, Aris T.
title: Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with Covid-19 in pregnancy: The INTERCOVID Study
date: 2021-12-20
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.12.032
sha: cbf2d666797d6ed69f5b84c3046dd8515913b08a
doc_id: 845426
cord_uid: sxvu7lci

Background Among non-pregnant individuals, diabetes mellitus (DM) and high body mass index (BMI) increase the risk of Covid-19 and its severity. Objective To determine whether DM and high BMI are risk factors for Covid-19 in pregnancy and whether gestational diabetes mellitus (GDM) is also associated with covid-19 diagnosis. Study Design INTERCOVID was a multinational study, conducted between March 2020 and February 2021 in 43 institutions from 18 countries, enrolling 2184 pregnant women ≥18 years; 2071 were included in these analyses. For each woman diagnosed with Covid-19, two non-diagnosed women delivering or initiating antenatal care at the same institution were also enrolled. Main exposures were pre-existing DM or high BMI (overweight/obesity defined as ≥25 kg/m2), and GDM in pregnancy. Main outcome was a confirmed diagnosis of Covid-19 based on an RT-PCR test, antigen test, antibody test, radiological pulmonary findings, or ≥2 predefined Covid-19 symptoms at any time during pregnancy or delivery. Relationships of exposures and Covid-19 diagnosis were assessed using generalized linear models with a Poisson distribution and log link function, with robust standard errors to account for model misspecification. We also conducted sensitivity analyses: 1) restricted to those with an RT-PCR or antigen test in the last week of pregnancy; 2) restricted to those with an RT-PCR or antigen test during the entire pregnancy; 3) generating values for missing data using multiple imputation; and 4) analyses controlling for month of enrollment. In addition, among those who were diagnosed with Covid-19, we examined whether having GDM, DM, or high BMI, increased risk for having symptomatic vs. asymptomatic Covid-19. Results Covid-19 was associated with preexisting DM (RR=1.94, 95% CI=1.55, 2.42), overweight/obesity (RR=1.20; 95% CI=1.06, 1.37), and GDM (RR=1.21; 95% CI=0.99, 1.46). The GDM association was specifically among women requiring insulin, whether they were of normal-weight (RR=1.79, 95% CI=1.06, 3.01) or overweight/obese (RR=1.77, 95% CI=1.28, 2.45). A somewhat stronger association with Covid-19 diagnosis was observed among women with pre-existing DM, whether they were of normal weight (RR=1.93, 95% CI=1.18, 3.17) or overweight/obese (RR=2.32, 95% CI=1.82, 2.97). When the sample was restricted to those with a RT-PCR or antigen test in the week before delivery or during the entire pregnancy, including missing variables using imputation, or controlling for month of enrollment, the observed associations were comparable. Conclusion DM and overweight/obesity are risk factors for Covid-19 diagnosis in pregnancy, and insulin-dependent GDM is also associated with the disease. It is therefore essential that those women with these co-morbidities are vaccinated.

Pregnant women with Covid-19 are at increased risk for severe illness compared to 103 other pregnant and non-pregnant women. [1] [2] [3] [4] Data from the multinational INTERCOVID study 104

showed that neonates born to women with Covid-19 are also at increased risk of morbidity and 105 mortality. 3 As with non-pregnant individuals, pregnant women with co-morbidities, such as 106 diabetes mellitus (DM) and overweight/obesity, are at risk for more severe Covid-19 107 outcomes, 1,4-6 including mortality. In non-pregnant individuals, DM, particularly among insulin 108 users, 7,8 and high body mass index (BMI) 9-11 not only increase risk of severe Covid-19 109 outcomes but SARS-CoV-2 infection itself. 110

As pregnant women were initially excluded from Covid-19 vaccine trials, 12 there are few 111 data on the safety of the Covid-19 vaccines during pregnancy. 13 Concerns about safety have 112 contributed to the lower levels of vaccine acceptance among pregnant compared to non-113 pregnant women. 14,15 As of 6 November 2021, only 35.3% of pregnant women in the United 114

States are vaccinated according to the most recent CDC report, with rates as low as 20.6% 115 among African Americans. 16 Table 2 for symptoms recorded and their frequencies).Two 'non-diagnosed' 141 women were enrolled for each Covid-19-diagnosed woman. The non-diagnosed women had to 142 be of similar gestation age (±2 weeks), to be receiving standard prenatal care from the same 143 institution, and to be the patients who were provided care immediately following the diagnosed 144

women. If a non-diagnosed woman was later diagnosed with Covid-19, she was maintained as 145 non-diagnosed, using an "intention to treat approach". 146

The Oxford Tropical Research Ethics Committee and all local ethics committees 147 approved the study. Women provided informed consent (oral or written) according to local 148 requirements, except if a waiver/exemption of such consent was granted by a local committee. 149

Information on pre-existing diabetes mellitus, body mass, and gestational diabetes 151 mellitus was abstracted from medical records using standardized forms. Women's height was 152 measured in duplicate using an adult stadiometer and recorded in centimeters (cm) to 1 decimal 153 place. Women's first trimester weight was measured; if unavailable, women were asked to 154 approximate weight before pregnancy. Woman's prepregnancy or first trimester weight was 155 recorded in kilograms (kg) to 1 decimal place. Body mass index (BMI) was calculated and 156 

We used the same centrally coordinated data management system established for the 164 INTERGROWTH-21 st Project (MedSciNet, London, United Kingdom). 23 All data were entered 165 locally into the online system with its comprehensive, built-in, quality control facility. Queries 166 could be dispatched immediately to the study sites, which provided continuously-cleaned 167 datasets for intermediate analysis. See https://intergrowth21.tghn.org/intercovid/intercovid-168 study-documents/ and previous publications for more details on study protocol and methods. 3,24 169

We constructed two primary models for the analysis. The first model examined the 171 association of Covid-19 diagnosis and GDM during the index pregnancy and pre-existing DM; 172 women with no history of either GDM or DM served as the reference group. BMI was also 173 included in this model. Initially, BMI was included as a 3-level variable but because there was no 174 clear dose response in the upper two levels, the categories of overweight or obese were 175 J o u r n a l P r e -p r o o f collapsed to maximize sample size in that statum. Women with BMI ≥25 kg/m 2 were compared 176 to those with BMI <25 kg/m 2 as the reference group. Covariates for the adjusted models were 177 selected using a directed acyclic graph, and included maternal age (continuous), parity 178 (nulliparous vs. parous), and tobacco use during pregnancy (yes vs. no). 179

Second, we examined the association of Covid-19 diagnosis and GDM, DM, and BMI in 180 eight subgroups of women, including those with: a) no GDM or DM, and normal weight 181 (reference); b) no GDM or DM, and overweight/obese; c) GDM not using insulin and normal 182 weight; d) GDM not using insulin and overweight/obese; e) GDM using insulin and normal 183 weight; f) GDM using insulin and overweight/obese; g) pre-existing DM and normal weight; and 184 h) pre-existing DM and overweight/obese. Maternal age, parity, and tobacco use were also 185 included in this model. 186

Relationships of exposures and Covid-19 diagnosis were assessed using generalized 187 linear models with a Poisson distribution and log link function, with robust standard errors to 188 account for model misspecification. Analyses were performed using Stata version 15.0. 25 189

As women with GDM are more likely to have closer clinical surveillance during 191 pregnancy, including for Covid-19 symptoms, we included in sensitivity analyses only those who 192 had a RT-PCR or antigen test within the last seven days of pregnancy or on the day of delivery 193

(n=937) (n=342 tested positive, n=595 tested negative)(Supplemental Figure 1 ). Due to the 194 proximity of testing to delivery, we assumed in these cases that the diagnosis of GDM, which 195 typically develops in the second half of pregnancy, very likely preceded the Covid-19 diagnosis. course of the study, we also conducted sensitivity analyses controlling for month of entry into 202 the study. 203

As noted above, missing values reduced the sample size by 113 women (n=33 for GDM 204 diagnosis, n=88 for BMI category, n=22 for tobacco use during pregnancy, and n=7 for previous 205 parity). In order to include these participants in sensitivity analyses, we generated values for all 206 missing data employing multiple imputation using chained equations with 10 iterations, which 207 brought the sample size back to 2184 women. We examined the same associations as above of 208

Covid-19 diagnosis in relation to GDM, DM, and BMI, as well as by subgroups (e.g., by insulin 209 use, body mass). 210

We recorded symptomalogy, but did not record information on severity of Covid-19. 211

Hence, we could only consider whether GDM, DM, and BMI were more likely to be related to 212 asymptomatic or symptomatic disease based on the women's self-report. We restricted these 213 models to women diagnosed with Covid-19 (n=672). We examined the association of having 214

Covid-19 symptoms vs. not having symptoms with GDM and DM (vs. women with neither 215 medical condition), and women who were overweight/obese (vs. women of normal BMI). We 216 repeated these analyses restricting the sample to those diagnosed by a positive RT-PCR or 217 antigen test within the last seven days of pregnancy or on the day of delivery (n=342). 218

Women enrolled in these analyses averaged 30.2 years of age (SD=6.1) and 43.4% 221 were nulliparous (Table 1) . GDM and DM were diagnosed in 9.4% (n=194) and 2.6% (n=53) of 222 In sensitivity analyses, when the sample was restricted to participants who had a Covid-241 19 RT-PCR or antigen test in the week before delivery, although the sample size was reduced 242 by more than 50%, the observed associations were similar (Figure 1 and Supplemental Table  243 3). Results were comparable when participants were restricted to those who received RT-PCR 244 or antigen tests at any time during pregnancy (Supplemental Table 4 ), when we controlled for 245 month of enrollment (Supplemental Table 5 ), or when we performed multiple imputation on 246 missing values (Supplemental Table 6 Although women with GDM overall were marginally at higher risk of Covid-19 diagnosis, we did 260 observe a significantly higher risk of Covid-19 diagnosis associated with GDM in insulin users; 261 the strength of the association approached that for DM, regardless of a woman's BMI. High BMI, 262 but not GDM or DM, was related to more symptomatic disease among those with Covid-19. Acilli posed the question as to the direction of the relationship between Covid-19 and 269 DM. 30 He concluded that although it is possible that SARS-CoV-2 can cause DM due to in vitro 270 evidence demonstrating the susceptibility of β-cells to SARS-CoV-2 and that any inflammatory 271 state can lead to insulin resistance, the more likely causal direction is that diabetes is a risk 272 factor for infection. Supporting this hypothesis, other researchers have shown that pancreatic 273 islet cells express the angiotensin-converting enzyme 2 (ACE2) receptor and that SARS 274 coronaviruses depend upon the ACE2 receptor for attachment and invasion into cells. 31 Zhao 275 and co-workers 32 underlined the essential roles for glycosylation in mediating ACE2 receptor 276 binding, and antigenic shielding of Sars-Cov-2 spikes. Specifically, the SARS-CoV-2 spike 277 protein, necessary for cell adhesion and invasion, and ACE2 are glycosylated or glycated. provides reassurance that GDM diagnoses preceded infection and supports the hypothesis that 290 the hyperglycemic state decreased the immune response to infection. [26] [27] [28] 37 The fact that pre-291 existing DM poses a higher risk than GDM, except in women who are insulin-dependent, is also 292 biologically plausible given that women with pre-existing disease have been in this 293 hyperglycemic state for a longer period of time. That GDM was only associated with Covid-19 294 diagnosis in women who were using insulin indicates that they had more severe GDM. 295

As in other observational epidemiologic studies, our findings could be explained by 296 uncontrolled confounding. However, the findings persisted after we controlled for potential 297 confounders identified by a directed acyclic graph, and the Covid-19 non-diagnosed and 298 diagnosed women were selected from the same hospital/country, gestation duration, and date, 299 assuring similar clinical practices by location over the course of the Covid-19 pandemic. 300 c. Clinical Implications: Covid-19 during pregnancy is known to increase severe 301 maternal morbidity and death, 2 particularly intubation and ICU admission. 3 Our data provide 302 additional information about the increased risk of infection associated with preexisting co-303 morbidities such as DM and high body mass, and the association with insulin-dependent GDM. 304

Women with these conditions should be monitored carefully for Covid-19 infection, glycemic 305 control, and weight gain. 38 Most importantly, unvaccinated pregnant women and those 306 considering pregnancy with these risk factors should be strongly encouraged to be vaccinated. 307

We employed data from a large-scale multinational study 308 that was specifically conducted to assess the symptoms and effects of Covid-19 during 309 pregnancy on maternal and neonatal outcomes when compared with pregnant women not-310 diagnosed with Covid-19 and enrolled concomitantly in the same facility, same level of care, and 311 at the same gestational age to minimize any selection bias. The study abstracted information on 312 maternal and neonatal outcomes and used rigorous data collection procedures, employing 313 structured forms and stringent quality control across 43 institutions to record morbidity. 314

The proportions of women diagnosed on the basis of Covid-19 symptoms alone and 315 those diagnosed by RT-PCR or antigen tests changed during the course of the study in each 316 country as laboratory testing became more available. It remains possible some of those not-317 diagnosed with Covid-19 may have included infected women who were asymptomatic and not 318 identified, either because routine testing was not available or because they became infected 319 after enrollment. This potential for misclassification would have led to more conservative 320

Although DM and high BMI preceded infection in all cases, GDM very likely preceded 322 infection for roughly half of those who were diagnosed by RT-PCR or antigen tests around the 323 time of delivery. It remains possible that women admitted to the hospital with severe 324 complications of pregnancy, such as uncontrolled GDM or DM, were more likely to be tested for, 325 or diagnosed with, Covid-19. However, the study design avoided such systematic bias by 326 selecting two women immediately after a diagnosed woman at the same level of care as the 327 reference group. In addition, when we restricted the analysis to those women who were PCR or 328 antigen tested, the results were similar, suggesting that this bias was minimal. 329

In contrast to women of high BMI with Covid-19, women with GDM or DM were not more We are very grateful to the contributing institutions and local researchers involved in the study. 371

The Appendix contains their details as well as details of the study committees. J o u r n a l P r e -p r o o f

Clinical manifestations, risk factors, and maternal and 377 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and 378 meta-analysis

An Update on Coronavirus Disease 2019 (COVID-19) and 380 Pregnancy

Maternal and Neonatal Morbidity and Mortality Among 383 Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational 384

Update: Characteristics of Symptomatic Women 386 of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy 387 Status -United States

A systematic review and meta-analysis of data on pregnant 390 women with confirmed COVID-19: Clinical presentation, and pregnancy and perinatal 391 outcomes based on COVID-19 severity

Coronavirus disease 2019 and obesity: one 394 pandemic meets another

Does Diabetes Increase the Risk of Contracting COVID-397 19? A Population-Based Study in Korea

Risks of and risk factors for COVID-19 disease 400 in people with diabetes: a cohort study of the total population of Scotland

Risk factors for SARS-CoV-2 among patients in 403 the Oxford Royal College of General Practitioners Research and Surveillance Centre 404 primary care network: a cross-sectional study

The negative impact of obesity on the occurrence 407 and prognosis of the 2019 novel coronavirus (COVID-19) disease: a systematic review and 408 meta-analysis

Obesity and risk of COVID-19: 410 analysis of UK biobank

mRNA Covid-19 Vaccines in Pregnant Women

Preliminary Findings of mRNA Covid-19

Vaccine Safety in Pregnant Persons

COVID-19 vaccination during pregnancy: coverage 418 and safety

COVID-19 vaccine acceptance among pregnant 421 women and mothers of young children: results of a survey in 16 countries

American College of Obstetricians and Gynecologists. COVID-19 Vaccination 427 Considerations for Obstetric-Gynecologic Care

Society for Maternal Fetal Medicine. Provider Considerations for Engaging in COVID-19 431 Vaccine Counseling With Pregnant and Lactating Patients

Vaccination Considerations for People Pregnant or Breastfeeding. Centers for 436 Disease Control and Prevention

Centers for Disease Control. COVID-19 Vaccine Monitoring Systems for Pregnant People

The Global Health Network. Essential Study Documents • INTERGROWTH-21 st

World Health Organization Regional Office for Europe. Body mass index -BMI

Managing data for the international, multicentre 450 INTERGROWTH-21st Project

Preeclampsia and COVID-19: results 453 from the INTERCOVID prospective longitudinal study

Stata Statistical Software: Release 15

Type 2 457 Diabetes and Pneumonia Outcomes

Urinary tract infections in patients with type 2 460 diabetes mellitus: review of prevalence, diagnosis, and management

Incidence of genital 463 infection among patients with type 2 diabetes in the UK General Practice Research 464 Database

High infectious morbidity in pregnant women with 467 insulin-dependent diabetes: an understated complication

Can COVID-19 cause diabetes? Nat Metab

Binding of SARS coronavirus to its receptor damages 472 islets and causes acute diabetes

Virus-Receptor Interactions of Glycosylated SARS-475

CoV-2 Spike and Human ACE2 Receptor

Advanced glycation end products and diabetic 478 complications

Commentary: COVID-19 in patients with diabetes

Factors determining the appearance of 483 glucose in upper and lower respiratory tract secretions

SARS-CoV-2 in diabetic pregnancies: a systematic 486 scoping review

Type 2 Diabetes and its Impact on the 489 Immune System

Weight Gain During Pregnancy: 492 Reexamining the Guidelines

COVID-19 Treatment Guidelines Panel. Clinical Spectrum of SARS-CoV-2 Infection

Australasian Diabetes in Pregnancy Society. Diagnostic Testing for Gestational 502 diabetes mellitus (GDM) during the COVID 19 pandemic: Antenatal and postnatal 503 testing advice

Royal College of Obstetricians & Gynaecologists. Guidance for maternal medicine 507 services in the coronavirus (COVID-19) pandemic

Royal College of Obstetricians & Gynaecologists. Guidance for maternal medicine 512 services in the evolving coronavirus (COVID-19) pandemic

Urgent Update -Temporary Alternative 516 Screening Strategy for Gestational Diabetes Screening During the COVID-19 Pandemic

 Table 1 . Real Time Polymerase Chain Reaction, antigen tests, and antibody tests for SARS-Cov-2 used in the participating centers.

Antibody tests  Abbott realtime SARS-Cov-2  Altona diagnostics RealStar SARS-CoV-2 RT-PCR  Aptima SARS-COV-2 Assay  Argene SARS-CoV-2 R-gene  BioFire® Respiratory 2. 1 J o u r n a l P r e -p r o o f Figure 1 . Risk of Covid-19 diagnosis according to gestational diabetes (GDM), insulin use, body mass index, and pre-pregnancy history of diabetes mellitus (DM), for participants in the INTERCOVID study, in the full population (n=2071) and the subset of women with a RT-PCR test in the week before or on day of delivery (N=937). a a Adjusted for maternal age, previous parity, and tobacco use during pregnancy.J o u r n a l P r e -p r o o f Figure 1 . Risk of Covid-19 diagnosis according to gestational diabetes (GDM), insulin use, body mass index, and pre-existing diabetes mellitus (DM), for participants in the INTERCOVID study, in the full population (n=2071) and the subset of women with a RT-PCR or antigen test in the week before or on day of delivery (N=937). a